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Owing to the aging of the population, our society
now faces an impending wave of age-related
neurodegenerative pathologies, the most significant
of which is Alzheimer’s disease. Currently, no
effective therapies for Alzheimer’s disease have been
developed. However, recent advances in the fields of
neural stem cells and human induced pluripotent
stem cells now provide us with the first real hope for
a cure. The recent discovery by Blurton-Jones and
colleagues that neural stem cells can effectively
deliver disease-modifying therapeutic proteins
throughout the brains of our best rodent models of
Alzheimer’s disease, combined with recent advances
in human nuclear reprogramming, stem cell research,
and highly customized genetic engineering, may
represent a potentially revolutionary personalized
cellular therapeutic approach capable of effectively
curing, ameliorating, and/or slowing the progression
of Alzheimer’s disease.now face an impending wave of the age-related neurode-The recent discovery that neural stem cells (NSCs) can ef-
fectively deliver disease-modifying therapeutic proteins
throughout the murine brain [1] provides hope for millions
worldwide who suffer from neurodegenerative disease. In
this commentary, I will attempt to place this important re-
search in a broader historical, technological, and scientific
context.
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2014our bodies and minds [2]. Gilgamesh’s ancient rejuven-
ation research proposal is as follows:
There is a plant that looks like a box-thorn, it has
prickles like a dogrose, and will prick one who
plucks it. But if you can possess this plant, you’ll be
again as you were in your youth.
This plant, Ur-shanabi, is the ‘Plant of Heartbeat’,
with it a man can regain his vigour.
To Uruk-the-sheepfold I will take it,
to an ancient I will feed some and put the plant to
the test! [2]
This goal has become a critical issue in modern times
as technological advances have permitted remarkable in-
creases in both human life expectancy and the percent-
age of the adult population surviving into old age [3].
However, the discovery of technologies to extend our
lives has far outpaced our ability to maintain our minds
as we age, and our rapidly aging population means we
generative pathology, Alzheimer’s disease (AD). Fore-
casts indicate that by 2050, in the United States alone,
over 13 million people will suffer from AD [4]. Novel
cellular therapies built on new technologies are begin-
ning to be developed for a broad range of diseases, and
AD offers a potentially promising indication.
NSCs, derived from pluripotent stem cells, are capable
of improving cognitive function in preclinical rodent
models of AD [5,6]. However, NSCs alone do not re-
move the amyloid-beta (Aβ) plaques, which (alongside
tau-based neurofibrillary tangles) may represent a partial
cause of the AD pathology. Neprilysin is a potent pro-
teolytic enzyme that is the rate-limiting enzyme involved
in the degradation of Aβ and is found at decreased levels
in AD brains. Although virally mediated delivery of
neprilysin can reduce Aβ pathology in murine brains,
the potential application of this viral approach for muche licensee has exclusive rights to distribute this article, in any medium, for 12
e, the article is available under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Byrne Stem Cell Research & Therapy Page 2 of 32014, 5:72
http://stemcellres.com/content/5/3/72larger human brains is restricted because of its limited
radius of infectivity. NSCs offer a potential solution to
this clinical bottleneck of narrow viral delivery. NSCs
are highly migratory in nature and thus may be suitable
for delivering secreted neuro-therapeutics throughout
the entire human brain, an activity that NSCs could per-
form alongside their other putative cognitive functional
improvements. These NSCs could be genetically modi-
fied to secrete neprilysin or other therapeutic transgenes
(or both) for the treatment of AD and other neurode-
generative pathologies, such as Parkinson’s disease,
stroke, and amyotrophic lateral sclerosis.
Blurton-Jones and colleagues have now demonstrated
that NSCs can effectively deliver disease-modifying
therapeutic proteins throughout the brain of our best ro-
dent models of AD [1]. They generated murine NSC lines
that overexpressed neprilysin, and subsequently trans-
planted these cells into transgenic models [1]. The NSCs
survived and continued to function for at least several
months post transplantation, they markedly reduced the
Aβ pathology associated with AD, and they enhanced
synaptic connectivity [1]. This exciting work brings us
one step closer to advancing NSC-based biologics into
therapies for AD. However, it is important to note thatFigure 1 Developing the neural stem cell-based approach for treating A
stem cells (iPSCs) and their neural stem cell (NSC) derivatives, alongside saf
cellular therapy for Alzheimer’s disease. Clinically relevant human iPSCs (pa
NSCs, and (as shown on the right) stained Pax6 (green), Sox1 (red) and DA
Patricia Phelps, and James Byrne. See JA Byrne, unpublished data, 2014 andthe commonly used human whole fetal graft [7], or NSCs
derived from fetal tissue, would not be immunologically
matched to the recipient, as it was in the study by
Blurton-Jones and colleagues. It is unclear how effective
this allogeneic transplantation would be in a somewhat
immuno-privileged area, such as the brain. However, re-
cent research demonstrates that significantly higher
numbers of autologous (as opposed to allogeneic)
neurons have survived in the primate brain following
transplantation [8]. A potential solution to this immune
rejection problem would be the lifelong administration of
immunosuppressive drugs to the patient in order to
minimize the immune response in the brain. However,
immunosuppressive drugs are expensive, inconvenient,
and toxic. Moreover, previous research suggests that they
do not appear to significantly improve allogeneic graft
survival and may even reduce it [7], making the proposed
immunosuppressive drug solution less than ideal.
An alternative approach, which has become increasingly
feasible in light of recent discoveries, would be to generate
autologous NSCs from human induced pluripotent stem
cells (hiPSCs), which themselves have been derived from
suitable patient cells, such as skin cells (Figure 1). These
cells could be genetically modified in a manner similarlzheimer’s disease. The concept of using human induced pluripotent
e-harbor targeted genetic engineering, to develop a personalized
ssage 7) were derived from skin punch biopsies, differentiated into
PI (blue). The figure is based on unpublished data of Kaitlin Ingraham,
[10].
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Blurton-Jones and colleagues. However, there are concerns
that randomly integrated viral vectors (as used in
approaches such as the study by Blurton-Jones and
colleagues) may induce insertional mutagenesis in a subset
of cells, which then would present an increased neoplasm
risk [9]. The optimal method for genetic modification of
hiPSC-derived NSCs would therefore probably involve
avoiding this randomly integrated viral vector approach.
One solution to this insertional mutagenesis problem
would be the use of powerful, flexible, and inexpensive
genome-editing technologies, such as the recently discov-
ered CRISPR/Cas9 system, for safe-harbor-based targeting
in hiPSCs. It is anticipated that this safe-harbor framework
will soon enable scientists and clinicians to generate hiPSC-
NSCs that are genetically modified to express almost any
other therapeutically relevant factor without risking ran-
dom insertional mutagenesis. Recent reports indicate that
implanted iPSC-derived NSCs have demonstrated the abil-
ity to survive, migrate, and differentiate and to restore lost
neurological function [11]. Such reports and the astonish-
ing pace of stem cell-based regenerative medicine provide
hope that new advances will continue to resolve the clinical
hurdles faced by hiPSC-based therapeutics for neurodegen-
erative diseases [9].
In conclusion, modified NSCs may represent a critically
needed solution to the inevitably increasing prevalence of
AD in contemporary society.
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